Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of QR12000 vs Sacubitril/valsartan in Essential Hypertension
NCT06716970Phase 3Not yet recruiting
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QR12000 in essential hypertension (3 arms), sponsored by Wuhan Createrna Science and Technology Co., Ltd. Primary endpoint: Change From Baseline in Mean Sitting Systolic Blood Pressure at 8 weeks. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
QR12000
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06716970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06716970.